Submitted by Brian Vuillemenot and Sven Korte, Chairpersons of the 2015 Continuing Education course AM04.
Are you planning on developing a therapeutic molecule for direct Central Nervous System (CNS) administration? Interested in neurological diseases? Or just fascinated with everything to do with the miracle of evolution that is the human brain? If so, enrolling in the Society of Toxicology (SOT) 2015 Continuing Education (CE) course “Safety Evaluation of CNS Administered Therapeutics—Study Design, Dose Routes, and Data Interpretation” should be a no-brainer! Many neurological diseases are inadequately treated by conventional systemic drug delivery. Due to the recent increases in the prevalence of these diseases and the inability of most systemically administered therapies to cross the blood brain barrier, direct CNS delivery will play an increasing role in the treatment of neurological disease in the years to come.
Nonclinical safety evaluation of molecules administered directly to the CNS has many unique considerations compared to traditional assessment of systemically administered molecules. This CE course will feature the collective experience of world leaders in developing CNS administered therapeutics. They will discuss the technical challenges of preclinical intrathecal/intracerebroventricular/intraparenchymal studies, design of Investigational New Drug (IND)-enabling programs, evaluation of results, and considerations for special endpoints. The course is intended for pathologists, toxicologists, administrators, and regulatory personnel who may need to design, conduct, or review these complicated but increasingly worthwhile investigations.
We invite you to register for the AM04 CE course today! Access a full listing of the CE courses at the 2015 SOT Annual Meeting website.